z-logo
Premium
Theophylline serum protein binding in obstructive airways disease
Author(s) -
Lesko Lawrence J,
Tabor Kenneth J,
Johnson Brian F
Publication year - 1981
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1981.110
Subject(s) - theophylline , bronchodilator , albumin , free fraction , medicine , serum albumin , plasma protein binding , pharmacokinetics , dosing , chemistry , endocrinology , pharmacology , asthma
The percentage of theophylline bound to protein in sera obtained from patients with obstructive airways disease was determined by ultrafiltration. The bound theophylline fraction in 71 serum specimens collected from 51 patients was 60.7 ± 10.0% ( x ± SD) and ranged from 30.8% to 83.2%. The correlation between unbound serum theophylline concentration and total concentration (range 0.8 to 90 mg/l) was linear (r = 0.97, p < 0.001). Theophylline binding correlated poorly with serum albumin (r = 0.39) and total serum protein (r = 0.35), although the correlations were statistically significant (p < 0.05). Theophylline binding in women did not differ from that in men. The extent of theophylline binding in younger patients was greater than in patients over 55 yr (64.3 ± 8.5% and 57.0 ± 10.4%, p < 0.005). Variation in theophylline binding in 12 patients from whom two or more serum samples were collected was relatively small. Analysis of variance showed interpatient variation in theophylline binding (p < 0.01) but not between sampling occasions in the same patient. The demonstrated variability in serum protein binding of theophylline should influence theophylline distribution and elimination kinetics and may be another determinant of clinical response. Patients with lower binding levels should have higher plasma levels of unbound drug after a loading dose and will need more frequent dosing. Clinical Pharmacology and Therapeutics (1981) 29 , 776–781; doi: 10.1038/clpt.1981.110

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here